Chartwell Pharmaceuticals, a contract manufacturer providing Rx solid dosage, packaging, and analytical services, recently implemented Adents software to assure compliance with current and future track & trace deadlines. Adents Seriza software has been incorporated to serialize products from several bottling lines all serialized products at Chartwell’s Congers, NY facility.
 
Following the decision to purchase a new NJM bottle labeling machine, Chartwell sought a serialization solution that could be implemented quickly, was hardware-agnostic, and would meet the upcoming November DSCSA requirements.
 
Chartwell’s line processed bottles with widely differing specifications, varying in size from 25-count to 2000-count at speeds of up to 150 bottles per minute. The new labeler, an NJM Trotter model TRW-126, was outfitted with a Cognex In-Sight series camera, and integrated with a VideoJet thermal transfer printer.
 
The labeler’s position at a multi-line convergence point was important.  Chartwell wanted to avoid the need for a second or third labeler, which many serialization vendors were proposing to prevent product backup. The desired serialization solution needed to be compatible with equipment from different manufacturers, as well as handle widely varying products at a high rate of efficiency.
 
At the site level, Adents Seriza employs a centralized configuration and process software called Adents Supervisor, which enables interface with ERP and EPCIS systems, multi-line configuration and serialization parameters management for country-specific requirements. At the line level, process execution software called Adents Pilot connects to site-level software and operates with a variety of line equipment to provide unit serialization, multi-level aggregation and rework.
 
“Adents Seriza enabled Chartwell Pharmaceuticals to process over a million units in just the first month of production,” said Christophe Devins, chief executive officer of Adents, “This quickly developed total trust in our software’s ability to satisfy not only current deadlines, but future global pharmaceutical regulatory mandates coming in the years ahead.”